CoChat

How glucagon-like peptide 1 receptor agonists work

Open access

The DOI matches its Crossref record; 99 of the 99 references it cites were found in a registry or an index.

Abstract

In recent years, glucagon-like peptide 1 receptor agonists (GLP-1RAs) have become central in the treatment of type 2 diabetes (T2D). In addition to their glucose-lowering properties with low risk of hypoglycaemia, GLP-1RAs reduce body weight and show promising results in reducing cardiovascular risk and renal complications in high-risk individuals with T2D. These findings have changed guidelines on T2D management over the last years, and GLP-1RAs are now widely used in overweight patients with T2D as well as in patients with T2D and cardiovascular disease regardless of glycaemic control. The currently available GLP-1RAs have different pharmacokinetic profiles and differ in their ability to improve glycaemia, reduce body weight and in their cardio- and renal protective potentials. Understanding how these agents work, including insights into their pleiotropic effects on T2D pathophysiology, may improve their clinical utilisation and be useful for exploring other indications such as non-alcoholic steatohepatitis and neurodegenerative disorders. In this review, we provide an overview of approved GLP-1RAs, their clinical effects and mode of action, and we offer insights into the potential of GLP-1RAs for other indications than T2D. Finally, we will discuss the emerging data and therapeutic potential of using GLP-1RAs in combinations with other receptor agonists.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1530/ec-21-0130

Cites

99 of 99 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Possible actions of glucagon-like peptide 1 (GLP-1) and the GLP-1 receptor agonists (GLP-1RAs) on various tissue. The applied colour code indicates whether the effect on the target tissue has been observed in preclinical studies (blue boxes), at physiological levels of GLP-1 in clinical studies (green boxes) or after treatment with GLP-1RAs (red boxes) (1, 2). The figure illustrates GLP-1 (7–36) amide.
Figure 1 Possible actions of glucagon-like peptide 1 (GLP-1) and the GLP-1 receptor agonists (GLP-1RAs) on various tissue. The applied colour code indicates whether the effect on the target tissue has been observed in preclinical studies (blue boxes), at physiological levels of GLP-1 in clinical studies (green boxes) or after treatment with GLP-1RAs (red boxes) (1, 2). The figure illustrates GLP-1 (7–36) amide.CC BY-NC · PubMed Central
Figure 2 Results from clinical trials comparing the GLP-1 receptor agonists (GLP-1RAs) head-to-head in phase III trials. Left panels are trials comparing short-acting GLP-1RAs (97). Middle panels are trials comparing a short-acting GLP-1RA with a long-acting GLP-1RA (7, 98, 99, 100). Right panel are trials comparing long-acting GLP-1RAs (101, 102, 103, 104, 105, 106). Asterisk (*) represents significant differences when comparing the GLP-1RAs.
Figure 2 Results from clinical trials comparing the GLP-1 receptor agonists (GLP-1RAs) head-to-head in phase III trials. Left panels are trials comparing short-acting GLP-1RAs (97). Middle panels are trials comparing a short-acting GLP-1RA with a long-acting GLP-1RA (7, 98, 99, 100). Right panel are trials comparing long-acting GLP-1RAs (101, 102, 103, 104, 105, 106). Asterisk (*) represents significant differences when comparing the GLP-1RAs.CC BY-NC · PubMed Central
Figure 3 Possible cardiovascular actions of glucagon-like peptide 1 (GLP-1) and GLP-1 receptor agonists (GLP-1RAs).
Figure 3 Possible cardiovascular actions of glucagon-like peptide 1 (GLP-1) and GLP-1 receptor agonists (GLP-1RAs).CC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 99 references

Research works printed but not linked: 1

  1. [89]A study of Tirzepatide (LY3298176) compared with dulaglutide on major cardiovascular events in participants with Type 2 diabetes (SurPASS-CVOT). (available at: https://clinicaltrials.gov/ct2/show/NCT04255433) 37758044

Cited by

See all 71

Metadata

Authors
Andreasen, C. R., Andersen, A., Knop, F. K., & Vilsbøll, T.
Affiliations
University of Copenhagen (DK)
Corresponding author
Vilsbøll, Tina
Venue
Endocrine Connections
Published
2021-07-01
Volume
10
Issue
7
Pages
R200-R212
ISSN
2049-3614 (ISSN-L)
OpenAlex
W3171499734
Cited by
71
References
99
Citations by year
2026: 22 · 2025: 18 · 2024: 15 · 2023: 7 · 2022: 6 · 2021: 3
FWCI
1.19
Type
journal article
Language
en
Open access
Locations
  • Endocrine Connections (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • Research at the University of Copenhagen (University of Copenhagen) (publishedVersion, cc-by-nc)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • Amgen
  • Eli Lilly and Company
  • AstraZeneca
  • Sanofi
  • Gilead Sciences
  • Steno Diabetes Center Copenhagen (SDCC 3.F CMP)
  • Novo Nordisk
  • Novo Nordisk Fonden (NNF15OC0016230, NNF12OC1015904, NNF16OC0020224, NNF20SA0062832, NNF17OC0028300, NNF17OC0029438)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
  • Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
Keywords
GLP-1 receptor agonists, type 2 diabetes, blood glucose reduction, weight loss, cardiovascular risk reduction, renal protection, pharmacokinetics, pleiotropy, nonalcoholic steatohepatitis, neurodegenerative diseases, combination therapy, receptor agonists

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: How glucagon-like peptide 1 receptor agonists work. https://app.cochat.ai/papers/10.1530/ec-21-0130
The paper
Andreasen, C. R., Andersen, A., Knop, F. K., & Vilsbøll, T. (2021). How glucagon-like peptide 1 receptor agonists work. Endocrine Connections. https://doi.org/10.1530/ec-21-0130

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.